Daily Cosmetic Research Analysis
Safety and efficacy in cosmetic medicine are highlighted by: a randomized, double-blind split-face trial showing protease-treated royal jelly cream improves periorbital wrinkles with mechanistic signals; a UK survey linking specific comorbidities to higher botulinum toxin adverse events; and a systematic review mapping foreign-body granulomas after collagen-stimulatory fillers with practical management insights. Together, these studies inform product selection, risk stratification, and complicat
Summary
Safety and efficacy in cosmetic medicine are highlighted by: a randomized, double-blind split-face trial showing protease-treated royal jelly cream improves periorbital wrinkles with mechanistic signals; a UK survey linking specific comorbidities to higher botulinum toxin adverse events; and a systematic review mapping foreign-body granulomas after collagen-stimulatory fillers with practical management insights. Together, these studies inform product selection, risk stratification, and complication management.
Research Themes
- Aesthetic procedure safety surveillance
- Mechanism-informed cosmeceuticals
- Complication management of collagen-stimulatory fillers
Selected Articles
1. Effect of Protease-Treated Royal Jelly Extract on Facial Wrinkles: A Placebo-Controlled, Double-Blind, Parallel-Group Study.
In a double-blind, split-face randomized study of 70 Japanese women over 12 weeks, a protease-treated royal jelly cream significantly reduced crow’s feet wrinkle depth versus placebo, increased stratum corneum hydration and dermal thickness, and reduced cheek bacterial microbiome abundance. Ex vivo, COL17A1 (an epidermal stem cell function marker) was upregulated with pRJ versus placebo, suggesting a mechanistic basis.
Impact: First randomized clinical demonstration of wrinkle improvement with a cosmeceutical linked to stem cell-associated markers and microbiome modulation, integrating clinical and mechanistic endpoints.
Clinical Implications: Supports considering pRJ-containing creams for periorbital rhytides, while encouraging dermatologists to monitor durability and safety and to counsel patients that benefits were shown over 12 weeks in Japanese women. The COL17A1 and microbiome signals provide hypotheses for personalized skincare and future biomarker-driven product development.
Key Findings
- Reduced maximum and average depth of crow’s feet wrinkles versus placebo after 12 weeks.
- Increased stratum corneum water content and dermal thickness in the pRJ group.
- Significant decrease in the relative amount of cheek bacterial microbiome only with pRJ.
- Ex vivo upregulation of COL17A1 with pRJ versus placebo cream.
Methodological Strengths
- Double-blind, randomized split-face design minimizing inter-individual variability.
- Multi-modal endpoints (objective wrinkle metrics, hydration, dermal thickness, microbiome, ex vivo mechanistic marker).
Limitations
- Single-ethnicity cohort (Japanese women) and 12-week duration limit generalizability and long-term inference.
- Ambiguity around trial registration and the exact parallel-group/split-face allocation may affect reproducibility.
Future Directions: Larger, multi-ethnic, preregistered RCTs with longer follow-up, dose–response assessment, and in vivo confirmation of stem-cell and microbiome mechanisms; explore biomarker-driven responder stratification.
BACKGROUND: No clinical trials have reported on the wrinkle-improving effects of cosmetics which activate stem cells in vitro. AIMS: To evaluate the anti-wrinkle effects of protease-treated royal jelly (pRJ)-containing cream application to the skin. MATERIALS & METHODS: Seventy healthy Japanese women concerned about skin aging were treated with pRJ-containing cream or placebo for 12 weeks using the split-face method in a placebo-controlled, double-blind, parallel-group study. RESULTS: The pRJ-containing cream group showed an improvement in the maximum depth and average depth of the biggest wrinkle in the crow's feet wrinkle, along with increased water content of the stratum corneum and dermal thickness, compared to the placebo group. Significant decreases in the relative amount of bacterial microbiome of the cheeks were observed only in the pRJ-containing cream group. In the ex vivo study, expression of COL17A1, epidermal stem cell function marker, was significantly up-regulated with the use of the pRJ-containing cream compared with the placebo cream. CONCLUSION: This is the first study to demonstrate the wrinkle-improving effects of pRJ. Our results suggest that pRJ not only controls stratum corneum water content, dermal thickness, and bacterial microbiome, but also affects stem cell competition and mesenchymal stem cell activation. pRJ can reduce or eliminate certain skin concerns of women by improving age-related wrinkles.
2. The Association Between Existing Health Conditions and Adverse Events from Botulinum Toxins: Findings From a UK Cross-sectional Survey in 2024.
A large UK cross-sectional survey of 919 cosmetic BoNT users found significant associations between multiple comorbidities and adverse events, including markedly increased odds of nausea with skin disease (OR 22.95), type 1 diabetes (OR 110.34), chronic migraine (OR 7.69), and thyroid disorders (OR 6.18). Comorbid autoimmune, endocrine, neurologic, and psychiatric conditions also correlated with risks ranging from bruising and ptosis to mood disturbances and apparent treatment failure.
Impact: Provides actionable safety signals for pre-procedure risk stratification in cosmetic BoNT, supported by multivariable analysis in a large real-world cohort.
Clinical Implications: Screen for and counsel patients with autoimmune disease, type 1 diabetes, thyroid disorders, chronic migraine, skin disease, and psychiatric conditions prior to BoNT; consider dose adjustments, injection-site strategies, and closer follow-up, and incorporate these risks into informed consent.
Key Findings
- In 919 BoNT users, several comorbidities significantly increased odds of adverse events.
- Nausea risk increased with skin disease (OR 22.95), type 1 diabetes (OR 110.34), chronic migraine (OR 7.69), and thyroid disorders (OR 6.18).
- Autoimmune, endocrine, neurologic, and psychiatric conditions were linked to broader risks (e.g., bruising, ptosis, mood disturbance, neuromuscular weakness, apparent treatment failure).
Methodological Strengths
- Large sample size with multivariable logistic regression to control for confounding.
- Captures both acute and long-term adverse events in real-world users.
Limitations
- Cross-sectional, self-reported survey limits causal inference and is subject to recall and selection biases.
- No clinical verification of adverse events; dosing, injection technique, and product heterogeneity may confound associations.
Future Directions: Establish prospective, clinician-verified registries to validate associations, quantify absolute risks by dose/technique/formulation, and develop pre-treatment risk scores.
BACKGROUND: There is growing demand for Botulinum toxin (BoNT) injections in the UK. However, there is a scarcity of research in relation to associations between medical conditions and BoNT adverse events. OBJECTIVES: To investigate cross-sectional associations between existing medical conditions and the likelihood of adverse events in a large sample of UK BoNT users. METHODS: A cross-sectional observational survey on individuals' (≥18 years) experiences and adverse events with cosmetic BoNT injections. Data were collected on participants age, gender, existing health conditions, acute and long-term adverse events following BoNT treatment. To investigate the association between pre-existing physical conditions and the occurrence of post-BoNT adverse effects, multivariable logistic regression models were performed. RESULTS: 919 participants who received BoNT were included in the analysis. Multivariable logistic regression revealed that several pre-existing physical and psychiatric conditions were significantly associated with increased odds of specific post-BoNT adverse effects. Notably, individuals with skin disease (odds ratio [OR] 22.95, 95% confidence interval [CI] 2.64-132.03, p=0.001), type 1 diabetes mellitus (OR 110.34, 95% CI 3.85-3381.06, p=0.002), chronic migraine (OR 7.69, 95% CI 1.84-27.61, p=0.003), and thyroid disorders (OR 6.18, 95% CI 1.27-23.44, p=0.012) demonstrated significantly higher odds of developing nausea following BoNT administration. Multiple other significant associations were found between numerous existing health conditions and numerous adverse events. CONCLUSIONS: This study found that autoimmune, endocrine, neurological, and mental health comorbidities significantly increase the likelihood of adverse outcomes, ranging from bruising and ptosis to mood disturbance, neuromuscular weakness, and apparent treatment failure.
3. Foreign Body Granulomas Reaction Related to Collagen Stimulatory Cosmetic Fillers: A Systematic Review.
This systematic review synthesized 117 reported cases of foreign-body granulomas after collagen-stimulatory fillers, finding highest proportions with PMMA and PLLA, median latency extended up to years, and nodules as the predominant presentation often in the perioral region. Management frequently included intralesional steroids, with many cases ultimately requiring surgical removal; nondegradable fillers showed higher and more delayed risk.
Impact: Offers consolidated, filler-specific safety patterns (timing, anatomic risk, management) that can inform patient counseling, consent, and complication pathways in aesthetic practice.
Clinical Implications: Counsel patients that nondegradable fillers (e.g., PMMA) carry higher and delayed granuloma risks, with the perioral region being high risk; discuss the likelihood of intralesional steroids and potential need for surgery; maintain long-term surveillance given latency up to 15 years.
Key Findings
- Among 117 cases, FBGs were most frequently associated with PMMA (35.04%) and PLLA (30.77%), followed by CaHA (27.35%), PCL (4.27%), and dextran-based fillers (2.56%).
- Latency to detection ranged from 1 week to 15 years (mean 20.18 months), with perioral region reported as high-risk.
- Nodules were the predominant presentation (82.91%); intralesional steroids were commonly used (21.37%), and many cases resolved after surgical removal.
- Nondegradable fillers had higher reported incidence and longer latency.
Methodological Strengths
- Systematic search across multiple databases (Web of Science, PubMed, Embase, Scopus) with filler-specific synthesis.
- Quantitative aggregation of latency, anatomic distribution, and management approaches.
Limitations
- Underlying evidence comprised mainly case reports/series with heterogeneity and likely publication/reporting bias.
- Lack of denominator data precludes incidence estimation and controlled comparisons.
Future Directions: Build prospective registries with standardized case definitions to estimate incidence and risk factors by filler type, dose, and technique; evaluate comparative effectiveness of management algorithms.
BACKGROUND: Collagen-stimulating filler has boomed as a new welcoming option in aesthetic treatments by activating the synthesis of endogenous collagen. However, hyperactive or inappropriate foreign-body stimulatory reactions may trigger intractable foreign body granulomas (FBGs). A comprehensive understanding of the FBGs associated with the augmenting effect of collagen biostimulants can help clinicians perform treatments in a safer and more effective way. METHODS: A literature search was conducted in Web of Science, PubMed, Embase, and Scopus to identify relevant clinical reports about the FBGs induced by six types of commercially available collagen stimulators up to August 2024. RESULTS: A total of 40 studies involving 117 patients were included. All but eight cases were women, and the mean age was 52.63 years (range 29-78 years). The most reported cases of FBGs were associated with PMMA (35.04%), followed by PLLA (30.77%), CaHA (27.35%), PCL (4.27%), and dextran-based filler (2.56%). The time until initial detection of FBGs reaction ranged from 1 week to 15 years (mean 20.18 months). Nodules were the most frequent complication (82.91%), followed by swelling (9.40%) and lumps (3.42%). The perioral region was the reported high-risk region for FBGs. Intralesional injection of steroids was performed most frequently (21.37%), but symptoms were often resolved through surgical removal. CONCLUSIONS: All included collagen biostimulators can induce FBGs reactions, with the nondegradable fillers having a higher reported incidence and a longer latency period. Timely recognition, diagnosis, and appropriate management of FBGs behind tissue augmentation with collagen stimulator filler are necessary for clinicians to optimize efficacy and minimize adverse events. LEVEL OF EVIDENCE: V.